Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML)
after initial cytoreduction has motivated modern efforts to combine synergistic active …
after initial cytoreduction has motivated modern efforts to combine synergistic active …
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
L Penter, Y Liu, JO Wolff, L Yang, L Taing… - …, 2023 - pubmed.ncbi.nlm.nih.gov
The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML)
after initial cytoreduction has motivated modern efforts to combine synergistic active …
after initial cytoreduction has motivated modern efforts to combine synergistic active …
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
L Penter, Y Liu, JO Wolff, L Yang, L Taing, A Jhaveri… - Blood, 2023 - europepmc.org
The challenge of eradicating leukemia for patients with acute myelogenous leukemia (AML)
following initial cytoreduction has motivated modern efforts to combine synergistic active …
following initial cytoreduction has motivated modern efforts to combine synergistic active …
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
L Penter, Y Liu, JO Wolff, L Yang, L Taing, A Jhaveri… - Blood, 2023 - ashpublications.org
The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML)
after initial cytoreduction has motivated modern efforts to combine synergistic active …
after initial cytoreduction has motivated modern efforts to combine synergistic active …
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
L Penter, Y Liu, JO Wolff, L Yang, L Taing… - …, 2023 - mdanderson.elsevierpure.com
The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML)
after initial cytoreduction has motivated modern efforts to combine synergistic active …
after initial cytoreduction has motivated modern efforts to combine synergistic active …
[HTML][HTML] Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
L Penter, Y Liu, JO Wolff, L Yang, L Taing, A Jhaveri… - Blood, 2023 - Elsevier
The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML)
after initial cytoreduction has motivated modern efforts to combine synergistic active …
after initial cytoreduction has motivated modern efforts to combine synergistic active …